Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies - Université Paris-Est-Créteil-Val-de-Marne
Article Dans Une Revue Nature Medicine Année : 2022

Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies

Olivier Schwartz
Connectez-vous pour contacter l'auteur
Virus et Immunité - Virus and immunity
Vaccine Research Institute [Créteil, France]
Thierry Prazuck
  • Fonction : Auteur
Centre Hospitalier Régional d'Orléans
Benjamin Terrier
Hôpital Cochin [AP-HP]
Emmanuel André
  • Fonction : Auteur
University Hospitals Leuven [Leuven]
Catholic University of Leuven = Katholieke Universiteit Leuven
Etienne Simon-Loriere
Génomique évolutive des virus à ARN - Evolutionary genomics of RNA viruses
Laurent Hocqueloux
Centre Hospitalier Régional d'Orléans
Luc Mouthon
Hôpital Cochin [AP-HP]
Guy Baele
Catholic University of Leuven = Katholieke Universiteit Leuven
Hugo Mouquet
Immunologie humorale - Humoral Immunology
Cyril Planchais
Immunologie humorale - Humoral Immunology
Lize Cuypers
  • Fonction : Auteur
University Hospitals Leuven [Leuven]
Artem Baidaliuk
Génomique évolutive des virus à ARN - Evolutionary genomics of RNA viruses
CV
Matthieu Prot
  • Fonction : Auteur
Génomique évolutive des virus à ARN - Evolutionary genomics of RNA viruses
David Veyer
  • Fonction : Auteur
  • PersonId : 767415
  • IdRef : 126541264
Génomique fonctionnelle des tumeurs solides = Functional Genomics of Solid Tumors [CRC]
Hôpital Européen Georges Pompidou [APHP]
Hélène Péré
Génomique fonctionnelle des tumeurs solides = Functional Genomics of Solid Tumors [CRC]
Hôpital Européen Georges Pompidou [APHP]
Caroline Charre
  • Fonction : Auteur
Université Paris Cité
Institut Cochin
Hôpital Cochin [AP-HP]
Marion Casadevall
  • Fonction : Auteur
Hôpital Cochin [AP-HP]
Yann Nguyen
Hôpital Cochin [AP-HP]
William-Henry Bolland
  • Fonction : Auteur
Virus et Immunité - Virus and immunity
École Doctorale Bio Sorbonne Paris Cité [Paris]
Françoise Porrot
Virus et Immunité - Virus and immunity
Florence Guivel-Benhassine
Virus et Immunité - Virus and immunity
Isabelle Staropoli
Virus et Immunité - Virus and immunity
Aymeric Seve
  • Fonction : Auteur
  • PersonId : 764974
  • IdRef : 177469501
Centre Hospitalier Régional d'Orléans
Delphine Planas
Virus et Immunité - Virus and immunity
Vaccine Research Institute [Créteil, France]
Piet Maes
Catholic University of Leuven = Katholieke Universiteit Leuven
Jérôme Hadjadj
  • Fonction : Auteur
Hôpital Cochin [AP-HP]
Timothée Bruel
Connectez-vous pour contacter l'auteur
Virus et Immunité - Virus and immunity
Vaccine Research Institute [Créteil, France]
CV

Résumé

The severe acute respiratory syndrome coronavirus 2 Omicron BA.1 sublineage has been supplanted in many countries by the BA.2 sublineage. BA.2 differs from BA.1 by about 21 mutations in its spike. In this study, we first compared the sensitivity of BA.1 and BA.2 to neutralization by nine therapeutic monoclonal antibodies (mAbs). In contrast to BA.1, BA.2 was sensitive to cilgavimab, partly inhibited by imdevimab and resistant to adintrevimab and sotrovimab. We then analyzed sera from 29 immunocompromised individuals up to 1 month after administration of Ronapreve (casirivimab and imdevimab) and/or Evusheld (cilgavimab and tixagevimab) antibody cocktails. All treated individuals displayed elevated antibody levels in their sera, which efficiently neutralized the Delta variant. Sera from Ronapreve recipients did not neutralize BA.1 and weakly inhibited BA.2. Neutralization of BA.1 and BA.2 was detected in 19 and 29 out of 29 Evusheld recipients, respectively. As compared to the Delta variant, neutralizing titers were more markedly decreased against BA.1 (344-fold) than BA.2 (nine-fold). We further report four breakthrough Omicron infections among the 29 individuals, indicating that antibody treatment did not fully prevent infection. Collectively, BA.1 and BA.2 exhibit noticeable differences in their sensitivity to therapeutic mAbs. Anti-Omicron neutralizing activity of Ronapreve and, to a lesser extent, that of Evusheld is reduced in patients' sera.

Domaines

Virologie

Isma Ziani  : Connectez-vous pour contacter le contributeur

https://pasteur.hal.science/pasteur-03654237

Soumis le : jeudi 28 avril 2022-14:39:59

Dernière modification le : mercredi 30 octobre 2024-13:10:39

Consulter le texte intégral

Dates et versions

pasteur-03654237 , version 1 (28-04-2022)

Identifiants

Citer

Olivier Schwartz, Thierry Prazuck, Benjamin Terrier, Emmanuel André, Etienne Simon-Loriere, et al.. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nature Medicine, 2022, ⟨10.1038/s41591-022-01792-5⟩. ⟨pasteur-03654237⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

PASTEUR EPHE CNRS UPEC CORDELIERS PSL SORBONNE-UNIVERSITE SU-SCIENCES UP-SANTE ANR FRM HUMORAL-IMMUNOLOGY U1222 VIR-IMMUN PASTEUR_UMR3569
78 Consultations
0 Téléchargements

Altmetric

Partager

More